Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07150208 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

T-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain Metastasis

Name: T-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain Metastasis — clinical trial record (NCT07150208)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: THUMB

StatusRecruiting

PhasePhase 2

SponsorFudan University

Started2025-10-20

View on ClinicalTrials.gov ↗

Amendment history

2026-09-26

Recruitment opened

Fudan University

624 trials monitored

See 9 trials at risk

Breast Cancer

5,180 trials monitored

See 256 trials at risk

A phase II, open-label, multicenter, randomized controlled trial exploring the efficacy and safety of Trastuzumab Deruxtecan combined with or without Bevicizumab in HER2-low breast cancer with brain metastasis.

Trial Details

NCT Number	NCT07150208
Lead Sponsor	Fudan University
Conditions	Breast Cancer With Brain Metastasis, HER2-low Expressing Breast Cancer
Enrollment	140 participants
Start Date	2025-10-20
Primary Completion	2027-09 (estimated)
Study Completion	2028-09 (estimated)
Updated on ClinicalTrials.gov	2026-09-25